Growth Activation Alone is Not Sufficient to Cause Metastatic Thyroid Cancer in a Mouse Model of Follicular Thyroid Carcinoma

Overview

Journal Endocrinology

Publisher Oxford University Press

Specialty Endocrinology

Date 2010 Feb 6

PMID 20133453

Citations 44

Authors

Changxue Lu

Li Zhao

Hao Ying

Mark C Willingham

Sheue-Yann Cheng

Affiliations

Soon will be listed here.

Abstract

TSH is the major stimulator of thyrocyte proliferation, but its role in thyroid carcinogenesis remains unclear. To address this question, we used a mouse model of follicular thyroid carcinoma (FTC) (TRbeta(PV/PV) mice). These mice, harboring a dominantly negative mutation (PV) of the thyroid hormone-beta receptor (TRbeta), exhibit increased serum thyroid hormone and elevated TSH. To eliminate TSH growth-stimulating effect, TRbeta(PV/PV) mice were crossed with TSH receptor gene knockout (TSHR(-/-)) mice. Wild-type siblings of TRbeta(PV/PV) mice were treated with an antithyroid agent, propylthiouracil, to elevate serum TSH for evaluating long-term TSH effect (WT-PTU mice). Thyroids from TRbeta(PV/PV)TSHR(-/-) showed impaired growth with no occurrence of FTC. Both WT-PTU and TRbeta(PV/PV) mice displayed enlarged thyroids, but only TRbeta(PV/PV) mice developed metastatic FTC. Molecular analyses indicate that PV acted, via multiple mechanisms, to activate the integrins-Src-focal adhesion kinase-p38 MAPK pathway and affect cytoskeletal restructuring to increase tumor cell migration and invasion. Thus, growth stimulated by TSH is a prerequisite but not sufficient for metastatic cancer to occur. Additional genetic alterations (such as PV), destined to alter focal adhesion and migration capacities, are required to empower hyperplastic follicular cells to invade and metastasize. These in vivo findings provide new insights in understanding carcinogenesis of the human thyroid.

Citing Articles

Clinical characteristics and therapeutic response of differentiated thyroid carcinoma with obesity and diabetes.

Wang X, Yu Y, Ji Y, Ma Z, Tan J, Jia Q BMC Cancer. 2023; 23(1):1077.

PMID: 37940857 PMC: 10631042. DOI: 10.1186/s12885-023-11591-x.

The Relationship between Thyrotropin Serum Concentrations and Thyroid Carcinoma.

Zhang X, Tian L, Teng D, Teng W Cancers (Basel). 2023; 15(20).

PMID: 37894384 PMC: 10605180. DOI: 10.3390/cancers15205017.

Activation of mitogen-activated protein kinase signaling and development of papillary thyroid carcinoma in thyroid-stimulating hormone receptor D633H knockin mice.

Eszlinger M, Stephenson A, Mirhadi S, Patyra K, Moran M, Khalil M Eur Thyroid J. 2023; 12(6).

PMID: 37855416 PMC: 10563634. DOI: 10.1530/ETJ-23-0049.

Pathogenesis of cancers derived from thyroid follicular cells.

Fagin J, Krishnamoorthy G, Landa I Nat Rev Cancer. 2023; 23(9):631-650.

PMID: 37438605 PMC: 10763075. DOI: 10.1038/s41568-023-00598-y.

ERBB2 as a prognostic biomarker correlates with immune infiltrates in papillary thyroid cancer.

Jin Y, Qiu X, He Z, Wang J, Sa R, Chen L Front Genet. 2022; 13:966365.

PMID: 36437939 PMC: 9682178. DOI: 10.3389/fgene.2022.966365.

References

Cheng S . Thyroid hormone receptor mutations in cancer. Mol Cell Endocrinol. 2004; 213(1):23-30. DOI: 10.1016/j.mce.2003.10.051. View

Zimonjic D, Kato Y, Ying H, Popescu N, Cheng S . Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice. Cancer Genet Cytogenet. 2005; 161(2):104-9. DOI: 10.1016/j.cancergencyto.2005.02.007. View

Owens L, Xu L, Dent G, Yang X, Sturge G, Craven R . Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol. 1996; 3(1):100-5. DOI: 10.1007/BF02409059. View

Furuya F, Lu C, Guigon C, Cheng S . Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. Steroids. 2008; 74(7):628-34. PMC: 3272696. DOI: 10.1016/j.steroids.2008.10.009. View

Garcia-Silva S, Aranda A . The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation. Mol Cell Biol. 2004; 24(17):7514-23. PMC: 506993. DOI: 10.1128/MCB.24.17.7514-7523.2004. View

Avizienyte E, Keppler M, Sandilands E, Brunton V, Winder S, Ng T . An active Src kinase-beta-actin association is linked to actin dynamics at the periphery of colon cancer cells. Exp Cell Res. 2007; 313(15):3175-88. DOI: 10.1016/j.yexcr.2007.04.037. View

Golubovskaya V, Virnig C, Cance W . TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog. 2007; 47(3):222-34. DOI: 10.1002/mc.20380. View

Dahlman T, Grimelius L, Wallin G, Rubin K, Westermark K . Integrins in thyroid tissue: upregulation of alpha2beta1 in anaplastic thyroid carcinoma. Eur J Endocrinol. 1998; 138(1):104-12. DOI: 10.1530/eje.0.1380104. View

Ensinger C, Obrist P, Mikuz G, Moncayo R, Riccabona G . beta 1-Integrin expression in papillary thyroid carcinoma. Anticancer Res. 1998; 18(1A):33-40. View

10.

Kim C, Vasko V, Kato Y, Kruhlak M, Saji M, Cheng S . AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology. 2005; 146(10):4456-63. DOI: 10.1210/en.2005-0172. View

11.

Weiss R, Refetoff S . Resistance to thyroid hormone. Rev Endocr Metab Disord. 2001; 1(1-2):97-108. DOI: 10.1023/a:1010072605757. View

12.

Schweppe R, Kerege A, French J, Sharma V, Grzywa R, Haugen B . Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009; 94(6):2199-203. PMC: 2690419. DOI: 10.1210/jc.2008-2511. View

13.

Cuenda A, Rousseau S . p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007; 1773(8):1358-75. DOI: 10.1016/j.bbamcr.2007.03.010. View

14.

Hoffmann S, Maschuw K, Hassan I, Reckzeh B, Wunderlich A, Lingelbach S . Differential pattern of integrin receptor expression in differentiated and anaplastic thyroid cancer cell lines. Thyroid. 2005; 15(9):1011-20. DOI: 10.1089/thy.2005.15.1011. View

15.

McLean G, Carragher N, Avizienyte E, Evans J, Brunton V, Frame M . The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer. 2005; 5(7):505-15. DOI: 10.1038/nrc1647. View

16.

Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter T . Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci U S A. 2000; 97(24):13209-14. PMC: 27204. DOI: 10.1073/pnas.230285997. View

17.

Roberts W, Ung E, Whalen P, Cooper B, Hulford C, Autry C . Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res. 2008; 68(6):1935-44. DOI: 10.1158/0008-5472.CAN-07-5155. View

18.

Ramsay A, Marshall J, Hart I . Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev. 2007; 26(3-4):567-78. DOI: 10.1007/s10555-007-9078-7. View

19.

Mitra S, Hanson D, Schlaepfer D . Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005; 6(1):56-68. DOI: 10.1038/nrm1549. View

20.

Brunton V, Frame M . Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol. 2008; 8(4):427-32. DOI: 10.1016/j.coph.2008.06.012. View